Suppr超能文献

印度三个合并队列中肺结核复发的临床和实验室危险因素

Clinical and laboratory risk factors for pulmonary tuberculosis recurrence in three pooled Indian cohorts.

作者信息

Krishnan Sonya, Gupte Nikhil, Paradkar Mandar, Gupte Akshay, Naik Mrunmayi, Raskar Swapnil, Suryavanshi Nishi, Pradhan Neeta, Gaikwad Sanjay, Karyakarte Rajesh, Lokhande Rahul, Luke Elizabeth Hanna, Thiruvengadam Kannan, Padmapriyadarsini Chandrasekaran, Sahasrabudhe Tushar, Barthwal Madhusudan, Kakrani ArjunLal, Viswanathan Vijay, Kornfeld Hardy, Gupta Amita, Golub Jonathan E, Mave Vidya

机构信息

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Johns Hopkins Center for Infectious Diseases in India, Johns Hopkins India, Pune, India.

出版信息

Front Tuberc. 2024;2. doi: 10.3389/ftubr.2024.1433975. Epub 2024 Jul 11.

Abstract

Some individuals with drug-susceptible pulmonary tuberculosis (PTB) experience tuberculosis recurrence. To evaluate the incidence of and risk factors for recurrence following completion of antituberculosis therapy, we pooled data from three prospective observational Indian PTB cohorts with 1164 individuals ≥14 years old included in our analysis. Ninety-five (8%) experienced recurrence with an 8.5 cases/100 person-years recurrence incidence rate (95% confidence interval 6.9-10.3) and a median time to recurrence of 6 months. On multivariable logistic regression, month 2 culture positivity (aHR 2.06; 95% CI 1.17-3.63), BMI <17 mg/kg (aHR 1.7; 95% CI 1.1-2.8), and male sex (aHR 1.92; 95% CI 1.05-3.51) were independent recurrence risk factors. Understanding risk factors for TB recurrence could enable clinicians to identify patients at risk for recurrence during antituberculosis therapy and may be used to alter patient care strategies, such as more frequent monitoring post treatment for high-risk individuals.

摘要

一些药物敏感型肺结核(PTB)患者会出现结核病复发。为了评估抗结核治疗结束后复发的发生率及危险因素,我们汇总了来自印度三个前瞻性观察性PTB队列的数据,分析纳入了1164名年龄≥14岁的个体。95名(8%)患者出现复发,复发发生率为8.5例/100人年(95%置信区间6.9 - 10.3),复发的中位时间为6个月。多变量逻辑回归分析显示,治疗第2个月培养阳性(调整后风险比[aHR] 2.06;95%置信区间1.17 - 3.63)、体重指数(BMI)<17 mg/kg(aHR 1.7;95%置信区间1.1 - 2.8)以及男性(aHR 1.92;95%置信区间1.05 - 3.51)是独立的复发危险因素。了解结核病复发的危险因素可使临床医生在抗结核治疗期间识别有复发风险的患者,并可用于改变患者护理策略,例如对高危个体在治疗后进行更频繁的监测。

相似文献

1
Clinical and laboratory risk factors for pulmonary tuberculosis recurrence in three pooled Indian cohorts.
Front Tuberc. 2024;2. doi: 10.3389/ftubr.2024.1433975. Epub 2024 Jul 11.
4
Associations of prior pulmonary tuberculosis with the incident COPD: a prospective cohort study.
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241239455. doi: 10.1177/17534666241239455.
5
Recurrent pulmonary tuberculosis after treatment success: a population-based retrospective study in China.
Clin Microbiol Infect. 2022 May;28(5):684-689. doi: 10.1016/j.cmi.2021.09.022. Epub 2021 Sep 30.
6
Recurrent Pulmonary Tuberculosis in China, 2005 to 2021.
JAMA Netw Open. 2024 Aug 1;7(8):e2427266. doi: 10.1001/jamanetworkopen.2024.27266.
9
Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
Cochrane Database Syst Rev. 2019 Dec 12;12(12):CD012918. doi: 10.1002/14651858.CD012918.pub2.

本文引用的文献

3
Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults.
BMJ Open. 2021 Mar 2;11(3):e044687. doi: 10.1136/bmjopen-2020-044687.
4
5
Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burden that cannot be ignored.
PLoS One. 2019 Jul 31;14(7):e0220507. doi: 10.1371/journal.pone.0220507. eCollection 2019.
6
Prevalence of dysglycemia and clinical presentation of pulmonary tuberculosis in Western India.
Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1280-1287. doi: 10.5588/ijtld.17.0474.
7
Relapse, re-infection and mixed infections in tuberculosis disease.
Pathog Dis. 2017 Apr 1;75(3). doi: 10.1093/femspd/ftx020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验